



## Newborn Screening for Lysosomal Storage Disorders

Guest Editors:

**Prof. Dr. David S. Millington**

Professor Emeritus of Pediatrics,  
Medical Genetics Division, Duke  
Medicine, Durham, NC 27709,  
USA

**Dr. Janice Fletcher**

Genetics and Molecular  
Pathology, SA Pathology at  
Women's and Children's  
Hospital, 72 King William Road,  
North Adelaide, SA 5006,  
Australia

Deadline for manuscript  
submissions:

**closed (30 September 2018)**

### Message from the Guest Editors

Newborn screening for lysosomal storage disorders (LSDs) has gained significant momentum during the past two years, stimulated by the addition of Pompe Disease and Hurler Syndrome to the recommended universal screening panel (RUSP).

New therapies, especially enzyme replacement and hematopoietic stem cell transplantation, have given new hope to families with affected children. Also, the development of fluorometric enzymatic assays for LSDs in dried blood pioneered by Nestor Chamoles in 2001 and boosted by Michael Gelb's tandem mass spectrometry method (2004) enables early detection of newborns. Multiplexing of LSD enzyme assays using either MS/MS or digital microfluidic fluorometry has facilitated high-throughput prospective screening for multiple LSDs.

Many have argued against screening for LSDs, citing the expense and variable efficacy of current treatment options and the preponderance of cases with later onset forms of disease, pseudodeficiency alleles, genetic variants of unknown significance and carriers. Post-analytical methods including statistical analytical tools and second-tier biochemical tests should help clarify these challenges.

